局灶不可逆电穿孔治疗局限性前列腺癌:171例单中心肿瘤学与功能结局
回顾性分析单中心171例原发性局灶不可逆电穿孔(IRE)治疗局限性前列腺癌的前瞻性数据库。中位随访35个月,84例接受监测活检者中8.3%存在显著靶内持续癌,14.3%存在显著靶外癌;尿控维持167/171(97.6%),性活跃问卷完成者中勃起功能维持94/112(84%)。
要点
- 局灶IRE后靶内显著癌消融率约92%,尿失禁与勃起功能障碍风险低。
- 靶内持续癌风险与术前ISUP评分、肿瘤位置、PSMA PET SUVmax≥10及PSAD>0.15无关。
- 需长期随访评估靶外进展风险。
核心结论
- 接受IRE后活检的患者中92%实现靶内显著癌消融,尿失禁和勃起功能障碍风险低。
- 局灶IRE治疗前列腺癌的短中期结局良好,但需长期随访靶外进展风险。
研究设计与样本
- 单中心前瞻性数据库的回顾性综述,纳入171例连续原发性局灶IRE治疗局限性前列腺癌病例。
- 中位随访35个月(范围3-90个月),治疗病灶中位直径11 mm(范围4-24 mm)。
主要发现
- 135例随访超过12个月的患者中,84例接受监测活检,8.3%存在显著靶内持续癌,14.3%存在显著靶外癌。
- 术前ISUP评分(p=0.8)、肿瘤位置(p>0.9)、诊断时低体积靶外癌(p=0.7)、前列腺PSMA PET SUVmax≥10(p=0.3)及PSAD>0.15(p=0.8)均未增加靶内持续或靶外进展风险。
- 尿控维持167/171(97.6%),性活跃且完成问卷者中勃起功能维持94/112(84%)。
- 大多数患者前列腺MRI为PI-RADS 4-5异常,25例(15%)为ISUP 4-5级癌。
临床怎么用
- 局灶IRE可作为局限性前列腺癌患者保留尿控和性功能的局部治疗选择。
- 术后应通过监测活检评估靶内持续和靶外进展,尤其关注靶外癌风险。
局限性
- 回顾性单中心设计,样本来自单一机构。
- 中位随访35个月,不足以评估长期靶外进展风险。
- 仅部分患者接受监测活检,功能结局基于问卷完成者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Focal irreversible electroporation (IRE) is an attractive choice for patients aiming to obtain local control of prostate cancer, while decreasing the postoperative risk of impotence and incontinence compared to whole-gland treatments. METHODS: Retrospective review of a single centre prospective database of 171 consecutive primary IRE procedures for localised prostate cancer. Primary outcomes include oncological infield and out-of-field progression. Secondary objectives include post-IRE continence and impotence. RESULTS: The median follow-up is 35 months (3-90 months). The median diameter of the treated lesions is 11 mm (4-24 mm). Most patients had PI-RADS 4-5 abnormalities on prostate MRI, and 25 patients (15%) had ISUP grade 4-5 cancer. Of the 135 patients with >12 months follow-up, 84 had a surveillance biopsy of whom 8.3% had significant infield persistence, with significant out-of-field cancer in 14.3%. There was no difference in the risk of infield cancer persistence regardless of the pre-IRE ISUP score (p = 0.8), or tumour location (p > 0.9). The presence of low volume out-of-field cancer at diagnosis did not increase the risk of post-IRE cancer persistence/progression (p = 0.7). The prostate PSMA PET SUVmax of ≥10 did not increase the risk of infield or out-of-field recurrence of cancer (p = 0.3). A PSAD > 0.15 did not increase the risk of infield persistence or out-of-field progression of cancer (p = 0.8). Urinary continence was maintained in 167/171 (97.6%), while erectile function was maintained in 94/112 (84%) of sexually active patients who completed questionnaires. CONCLUSIONS: Of the patients who proceeded to post-IRE biopsy, 92% had infield ablation of clinically significant cancer with a low risk of urinary incontinence or impotence. Focal IRE of prostate cancer has promising short to medium-term outcomes and is associated with low risks of impotence and incontinence. Long-term follow-up of out-of-field progression risk is required.
引用
- Mian Z, Gianduzzo T, Kua B, et al. Oncological and functional outcomes of focal irreversible electroporation for localised prostate cancer: a single institution series of 171 cases. Prostate Cancer Prostatic Dis. 2026. PMID: 42680821. doi:10.1038/s41391-026-01148-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。